Strs Ohio increased its position in shares of Acorda Therapeutics Inc. (NASDAQ:ACOR) by 30.8% during the second quarter, Holdings Channel reports. The fund owned 156,100 shares of the biopharmaceutical company’s stock after buying an additional 36,800 shares during the period. Strs Ohio’s holdings in Acorda Therapeutics were worth $3,981,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in ACOR. Deerfield Management Co. acquired a new position in Acorda Therapeutics during the first quarter worth about $27,228,000. Scopia Capital Management LP boosted its position in Acorda Therapeutics by 35.9% in the first quarter. Scopia Capital Management LP now owns 2,655,533 shares of the biopharmaceutical company’s stock worth $70,239,000 after buying an additional 702,110 shares in the last quarter. Prudential Financial Inc. boosted its position in Acorda Therapeutics by 238.8% in the first quarter. Prudential Financial Inc. now owns 339,652 shares of the biopharmaceutical company’s stock worth $8,984,000 after buying an additional 239,400 shares in the last quarter. State Street Corp boosted its position in Acorda Therapeutics by 11.5% in the first quarter. State Street Corp now owns 1,455,471 shares of the biopharmaceutical company’s stock worth $38,494,000 after buying an additional 149,960 shares in the last quarter. Finally, Spark Investment Management LLC boosted its position in Acorda Therapeutics by 108.8% in the first quarter. Spark Investment Management LLC now owns 268,300 shares of the biopharmaceutical company’s stock worth $7,096,000 after buying an additional 139,800 shares in the last quarter.
Acorda Therapeutics Inc. (NASDAQ:ACOR) traded up 0.19% during trading on Thursday, hitting $20.71. The stock had a trading volume of 487,993 shares. Acorda Therapeutics Inc. has a 52 week low of $20.18 and a 52 week high of $43.63. The company’s market cap is $954.52 million. The company has a 50-day moving average of $24.19 and a 200 day moving average of $25.84.
Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.07 EPS for the quarter, missing the Zacks’ consensus estimate of $0.18 by $0.11. Acorda Therapeutics had a negative net margin of 1.08% and a positive return on equity of 1.00%. The firm earned $127.45 million during the quarter, compared to analyst estimates of $128.33 million. During the same period last year, the business posted $0.31 EPS. The company’s revenue was up 12.1% on a year-over-year basis. On average, equities research analysts anticipate that Acorda Therapeutics Inc. will post $0.47 EPS for the current year.
A number of research analysts recently issued reports on ACOR shares. TheStreet cut Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. Leerink Swann started coverage on Acorda Therapeutics in a report on Tuesday. They issued a “market perform” rating and a $25.00 price target for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $65.00 price target on shares of Acorda Therapeutics in a report on Thursday, August 25th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $39.63.
In other Acorda Therapeutics news, insider Jane Wasman sold 3,750 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $20.78, for a total value of $77,925.00. Following the completion of the sale, the insider now owns 105,021 shares of the company’s stock, valued at $2,182,336.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.00% of the stock is owned by company insiders.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.